16 studies found for:    "Familial cold autoinflammatory syndrome"
Show Display Options
Rank Status Study
1 Completed
Has Results
Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-associated Periodic Syndromes:;   Familial Cold Autoinflammatory Syndrome;   Muckle Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Drug: Canakinumab (ACZ885)
2 Completed The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
Condition: Familial Cold Urticaria
Intervention: Drug: Kineret (anakinra)
3 Completed Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet
Condition: Cold Hypersensitivity
Interventions: Drug: Korean red ginseng;   Drug: Placebo
4 Active, not recruiting Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Drug: ACZ885
5 Recruiting Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Biological: ACZ885
6 Completed Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Drug: canakinumab
7 Completed
Has Results
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Conditions: Familial Cold Autoinflammatory Syndrome (FCAS);   Familial Cold Urticaria;   Muckle-Wells Syndrome (MWS);   Genetic Diseases, Inborn
Interventions: Drug: rilonacept 160 mg;   Drug: Placebo
8 Withdrawn A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
Conditions: Muckle Wells Syndrome;   Autoinflammatory;   Behcet's Disease
Intervention: Drug: XOMA 052
9 Unknown  The CAP-1 Trial: Stepwise Excavation Versus One Completed Excavation in Deep Caries
Conditions: Deep Caries Lesions;   Reversible Pulpitis
Intervention: Procedure: Stepwise Excavation, one completed excavation
10 Completed
Has Results
Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma
Condition: Pancreatic Adenocarcinoma
Interventions: Biological: modified CEA peptide (10mcg);   Biological: modified CEA peptide (100mcg);   Biological: modified CEA peptide (1000mcg)
11 Unknown  The CAP-2 Trial: Effect of Direct Pulp Capping Versus Partial Pulpotomy
Condition: Dental Pulp Exposure
Intervention: Procedure: Pulp capping and partial pulpotomy
12 Completed Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: CEA peptide 1-6D
13 Terminated Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
Conditions: Colorectal Cancer;   Esophageal Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastric Cancer;   Pancreatic Cancer;   Small Intestine Cancer
Interventions: Biological: carcinoembryonic antigen peptide 1-6D;   Biological: incomplete Freund's adjuvant;   Biological: sargramostim
14 Completed The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
Condition: Cryopyrin Associated Periodic Syndrome
Intervention: Drug: canakinumab (company code: ACZ885D)
15 Recruiting Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
Conditions: Cryopyrin-associated Periodic Syndromes (CAPS);   Familial Cold Autoinflam Syn (FCAS);   Muckle-wells Syn (MWS);   Neonatal Onset Multisystem Inflam Disease (NOMID)
Intervention:
16 Recruiting Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
Condition: Periodic Disease
Intervention:

Indicates status has not been verified in more than two years